$326.89
▲ +0.0% Today
as of Sep 4, 16:51 ET
Last 30 days
Recent Press Releases & News
Argus Adjusts Price Target on Labcorp Holdings to $370 From $310, Keeps Buy Rating
Labcorp Announces Enhanced Global Trial Connect Platform for Sponsors, Investigator Sites
Labcorp Launches Next Generation of Labcorp Global Trial Connect™ to Help Sponsors and Investigator Sites Navigate Clinical Trial Complexity
Overview
52-week range
$245
$342
85% of range
Avg surprise (last 2)
+4.0%
Avg reaction (last 2)
+5.8%
100% positive
Latest IV / EM
22%
EM ±3.4% · $330 · Sep 18
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Tue Jun 30, 2026 | Jun 2026 | $3.64 | — | — | — | — | financials |
| Tue Mar 31, 2026 | Mar 2026 | $3.35 | — | — | — | — | financials |
| Tue Sep 30, 2025 | Sep 2025 | $3.12 | — | — | — | — | financials |
| Thu Jul 24, 2025 | Jun/2025 | $4.35 | $4.14 | +5.1% | — | +6.9% | earnings |
| Tue Apr 29, 2025 | Mar/2025 | $3.84 | $3.73 | +3.0% | — | +4.7% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $2.00 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $2.43 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $2.69 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $2.11 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $2.12 | — | — | — | — | financials |
| Fri Mar 31, 2023 | Mar 2023 | $2.39 | — | — | — | — | financials |
Financials
Income statement (quarterly)
| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $3.73B | $3.54B | — | $3.56B | $3.53B | $3.35B | — | $3.28B |
| Cost of revenue | $2.62B | $2.52B | — | $2.54B | $2.48B | $2.40B | — | $2.38B |
| Gross profit | $1.11B | $1.01B | — | $1.03B | $1.05B | $948M | — | $904M |
| Operating income | $452M | $381M | — | $397M | $394M | $326M | — | $254M |
| Net income | $299M | $278M | — | $261M | $238M | $213M | — | $169M |
| EPS (diluted) | $3.64 | $3.35 | — | $3.12 | $2.84 | $2.52 | — | $2.00 |
Balance sheet (quarterly)
| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $142M | $981M | $532M | $598M | $647M | $369M | $1.52B | $1.52B |
| Inventory | $562M | $498M | $535M | $522M | $508M | $488M | $493M | $483M |
| Total current assets | $3.81B | $4.56B | $4.02B | $4.08B | $4.09B | $3.79B | $4.81B | $4.91B |
| Total assets | $18.53B | $19.09B | $18.39B | $18.26B | $18.06B | $17.60B | $18.38B | $18.61B |
| Long-term debt | $5.86B | $5.83B | $5.08B | $5.08B | $5.08B | $5.57B | $5.33B | $5.35B |
| Total liabilities | $9.91B | $10.34B | $9.76B | $9.55B | $9.57B | $9.28B | $10.31B | $10.43B |
| Total equity | $8.61B | $8.73B | $8.62B | $8.70B | $8.47B | $8.31B | $8.05B | $8.17B |